3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow Factor 8 deficiency, acquired: new trials by email Literature Review of Factor 8 deficiency, acquired trials Research Report on Factor 8 deficiency, acquired
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emicizumab in Patients With Acquired Hemophilia A emicizumab - Acquired Hemophilia A | Phase 2 | Active not recruiting | University of Washington | 51 | 2022-08-31 | 2025-11-05 |
| Study of TAK-672 in Participants With Acquired Hemophilia A TAK-672 - Acquired Hemophilia A | Phase 2 / Phase 3 | Completed | Takeda | 5 | 2021-04-09 | 2024-12-02 |
| Emicizumab in Acquired Hemophilia A Emicizumab Injection - Hemophilia A, Acquired | Phase 2 | Completed | GWT-TUD GmbH | 47 | 2021-03-23 | 2023-01-09 |
| Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A Bortezomib, Rituximab - Acquired Hemophilia A | Phase 2 | Unknown | Peking Union Medical College Hospital | 22 | 2018-10-10 | 2018-11-23 |
| Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A OBI-1 - Acquired Hemophilia A | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 29 | 2010-11-10 | 2021-05-13 |
| Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A Rituxan, prednisone - Hemophilia A | Phase 2 / Phase 3 | Terminated | Georgetown University | 2 | 2006-04-01 | 2017-02-10 |
Hemophilia A (2) · Blood Coagulation Disorders (1) · Coagulation Protein Disorders (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Blood Coagulation Disorders, Inherited (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hemic and Lymphatic Diseases (2) · Blood Coagulation Disorders (1) · Coagulation Protein Disorders (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Rituximab (2) · emicizumab (2) · Adrenal Cortex Hormones (1) · Bortezomib (1) · Factor VIII (1) · Prednisone (1)
Baxalta now part of Shire (1) · GWT-TUD GmbH (1) · Georgetown University (1) · Peking Union Medical College Hospital (1) · Takeda (1) · University of Washington (1)
United States (2) · Austria (1) · Canada (1) · China (1) · Germany (1) · India (1) · Japan (1) · United Kingdom (1)
Andreas Tiede, Prof. Dr. (1) · Craig Kessler, MD (1) · Rebecca Kruse-Jarres, MD, MPH (1) · Tienan Zhu (1)
PMID 25623166, PMID 29296693, PMID 37858328, PMID 39228858, PMID 40795229, PMID 42290320